Good Versus Evil: Changing the Approach to Hormone Replacement Therapy

Endocrinology

Volumn 144, Issue 11, 2003, Pages 4698-4699

  Hoffman, Gloria E ^a   Zup, Susan L ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACOLBIFENE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

BONE DENSITY; BREAST CANCER; CANCER RISK; COLON CANCER; DRUG EFFICACY; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; MENOPAUSE; NEUROPROTECTION; OSTEOLYSIS; OVARY CANCER; PRIORITY JOURNAL; SHORT SURVEY; SLEEP DISORDER; UTERUS CANCER; WEIGHT GAIN;

ANIMALS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; HUMANS; PIPERIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0242636887     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2003-1001     Document Type: Short Survey

References (23)

1. Resnick SM, Maki PM 2001 Effects of hormone replacement therapy on cognitive and brain aging. Ann NY Acad Sci 949:203-214
2. Wise PM, Dubal DB, Wilson ME, Rau SW, Bottner M 2001 Minireview: neuroprotective effects of estrogen-new insights into mechanisms of action. Endocrinology 142:969-973
3. Wise PM, Dubal DB, Wilson ME, Rau SW, Liu Y 2001 Estrogens: trophic and protective factors in the adult brain. Front Neuroendocrinol 22:33-66
4. Wise PM, Smith MJ, Dubal DB, Wilson ME, Krajnak KM, Rosewell KL 1999 Neuroendocrine influences and repercussions of the menopause. Endocr Rev 20:243-248
5. Singer CA, Rogers KL, Strickland TM, Dorsa DM 1996 Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett 212:13-16
6. Simpkins JW, Rajakumar G, Zhang YQ, Simpkins CE, Greenwald D, Yu CJ, Bodor N, Day AL 1997 Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg 87:724-730
7. Shi J, Bui JD, Yang SH, He Z, Lucas TH, Buckley DL, Blackband SJ, King MA, Day AL, Simpkins JW 2001 Estrogens decrease reperfusion-associated cortical ischemic damage: an MRI analysis in a transient focal ischemia model. Stroke 32:987-992
8. Sandyk R 1989 Estrogens and the pathophysiology of Parkinson's disease. Int J Neurosci 45:119-122
9. Paganini-Hill A, Ross RK, Henderson BE 1988 Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 297:519-522
10. Mattson MP, Robinson N, Guo Q 1997 Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1. Neuroreport 8:3817-3821
11. Kim H, Bang OY, Jung MW, Ha SD, Hong HS, Huh K, Kim SU, Mook-Jung I 2001 Neuroprotective effects of estrogen against β-amyloid toxicity are mediated by estrogen receptors in cultured neuronal cells. Neurosci Lett 302: 58-62
12. Green PS, Gridley KE, Simpkins JW 1996 Estradiol protects against β-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett 218:165-168
13. Goodman Y, Bruce AJ, Cheng B, Mattson MP 1996 Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons. J Neurochem 66:1836-1844
14. Dubal DB, Kashon ML, Pettigrew LC, Ren JM, Finklestein SP, Rau SW, Wise PM 1998 Estradiol protects against ischemic injury. J Cereb Blood Flow Metab 18:1253-1258
15. Bonnefont AB, Munoz FJ, Inestrosa NC 1998 Estrogen protects neuronal cells from the cytotoxicity induced by acetylcholinesterase-amyloid complexes. FEBS Lett 441:220-224
16. Behl C, Moosmann B, Manthey D, Heck S 2000 The female sex hormone oestrogen as neuroprotectant: activities at various levels. Novartis Found Symp 230:221-234
17. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ, WHI Investigators 2003 Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289:2673-2684
18. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD 2002 Postmenopausal hormone replacement therapy: scientific review. JAMA 288: 872-881
19. Hackenberg R, Hawighorst T, Filmer A, Nia A, Schulz K 1993 Medroxyprogesterone acetate inhibits the proliferation of estrogen-and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor. Breast Cancer Res Treat 25:217-224
20. Bentel J, Birrell S, Pickering M, Holds D, Horsfall D, Tilley W 1999 Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol 154:11-20
21. Luukkainen T 2003 Issues to debate on the Women's Health Initiative study: failure of estrogen plus progestin therapy for prevention of breast cancer risk. Hum Reprod 18:1559-1561
22. Labrie F, El-Alfy M, Berger L, Labrie C, Martel C, Bélanger A, Candas B, Pelletier G 2003 The combination of a novel selective estrogen receptor modulator with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology 144: 4700-4706
23. Bernardi F, Stomati M, Luisi S, Pieri M, Labrie F, Genazzani AR 2002 Effects of the new generation selective estrogen receptor modulator EM-652 and oral administration of estradiol valerate on circulating, brain, and adrenal β-endorphin and allopregnanolone levels in intact fertile and ovariectomized rats. Fertil Steril 77:1018-1027